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Abstract 
Background: Atrial fibrillation is one of the complications of rheumatic heart disease, with substantial morbidity 
and mortality. The prevalence and predictors of atrial fibrillation and its thrombo-embolic complications in 
Ethiopian patients with rheumatic heart disease are unknown. The objective of this study was to determine the 
prevalence and predictors of atrial fibrillation and its thromboembolic complications. 
Methods: A retrospective chart review of 500 patients with rheumatic heart disease at the adult cardiology clinic 
of Tikur Anbessa Specialized Hospital was carried out from 01 January to 31 June 2016. Data were entered into a 
pre-tested questionnaire and were analyzed using SPSS version 23. 
Results: Records of 500 patients (72% female) with electrocardiographic recordings and echocardiographic 
reports were available for analysis. Atrial fibrillation was found in 234 (46.8%) of the patients. Predictors of atrial 
fibrillation were found to be: age ≥50 years (p=0.01), left atrial size ≥45mm (p=0.01), the presence of mitral 
stenosis (p<0.01) and the presence of tricuspid regurgitation (p=0.01). Cardioembolic events were reported in 67 
(9.2%) patients, and the presence of atrial fibrillation (p=0.02) and sub-therapeutic anticoagulation status (p<0.01) 
were significant predictors of cardioembolic events. 
Conclusions and recommendations: The study reveals a high prevalence of atrial fibrillation and cardioembolic 
events in Ethiopian patients with rheumatic heart disease. Hence, active screening of atrial fibrillation and optimal 
anticoagulation are recommended.  [Ethiop. J. Health Dev. 2019;33(1):12-16] 
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Background 
Atrial fibrillation (AF) is a cardiac rhythm disorder 
where the normal sinus rhythm is replaced by a 
chaotic, ineffective atrial rhythm. AF is relatively 
common arrhythmia and may cause significant 
mortality and impair both functional status and the 
quality of life (1-3). In developed countries, coronary 
artery disease and hypertensive heart disease are the 
two most common causes, while rheumatic heart 
disease (RHD) is the major cause in developing 
countries such as Ethiopia (4). RHD causes 
considerable morbidity and mortality as a result of 
cardioembolic stroke, congestive heart failure and 
infective endocarditis. Carapetis and colleagues 
estimate that up to 7.5% of all strokes that occur in less 
developed countries could be a direct result of RHD 
(5). 
 
In Ethiopia, RHD is a significant cause of 
cardiovascular morbidity and mortality (6-9). 
According to previous studies, up to two-thirds of cases 
of AF in Ethiopian patients could be attributed to RHD 
(6-10, 11). AF is one of the main contributors of stroke 
in the young, worsening heart failure and mortality 
(12,13) (12,13). A retrospective study of stroke patients 
at Tikur Anbessa Hospital showed that 28.8% of 
strokes in the young (aged 15-44 years) were attributed 
to RHD (14). RHD patients with or without coexistent 
overt AF are predisposed to the development of 
cardioembolic stroke (15). For high-risk patients with 
AF, anticoagulation with rate and rhythm control is the 
main treatment modality. These high-risk patients 
include those with left atrial thrombus, previous 
systemic embolism, and rheumatic mitral stenosis (MS) 
(16). Several observational studies have documented 
lower rates of recurrent cerebral embolic events among 
RHD patients who receive warfarin (17,18). 
 
We are unaware of any study which has examined the 
prevalence and determinants of AF and its 
cardioembolic complications in Ethiopian RHD 
patients. Hence, this study aims to investigate the 
prevalence, determinants, anticoagulation status and 
complications of AF in Ethiopian patients with RHD at 
Tikur Anbessa Specialized Hospital, Addis Ababa, 
Ethiopia. The findings of the study will be valuable for 
planning preventive measures to reduce the 
complications of AF caused by RHD by showing the 
prevalence and determinants of the disease. 
 
Methods 
This was a retrospective review of medical records of 
500 RHD patients who had clinical follow-up at the 
adult cardiac clinic of Tikur Anbessa Specialized 
Hospital between January 2011 and January 2016. The 
hospital is the largest referral hospital in the country 
and provides cardiovascular care for patients older than 
13 years of age at adult cardiac clinic. All new 
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cardiovascular patients referred to the clinic are 
evaluated by cardiologists for diagnosis, initiation and 
optimization of treatment. 
 
Patients with a diagnosis of RHD who had both 
electrocardiographic (ECG) recordings and standard 
echocardiographic reports were included in the study. 
Echocardiography is currently the gold standard 
diagnostic test for RHD. Data on patient socio-
demographics, clinical characteristics – including the 
presence or absence of hypertension, diabetes mellitus, 
dyslipidemia, heart failure, current drug treatment, and 
history of cardioembolic events , average International 
Normalized Ratio (INR) test results done in the past six 
months and echocardiographic findings, were collected 
using a standardized pre-tested questionnaire. A 
presumed cardioembolic event was considered when 
imaging evidence of ischemic stroke and/or peripheral 
acute ischemic events were found in known RHD 
patients. 
 
Preliminary ECG readings were performed by senior 
medical residents and confirmed by a senior 
cardiologist (the investigator). Medical residents at 
Tikur Anbessa Hospital who were trained on the study 
protocol participated in the review of patients’ charts 
and collection of the research data. The investigators 
were also involved in the training of data collectors and 
supervision of data collection. Quality assurance of the 
data was made in a two-tier fashion. First, the 
supervisor checked for the completeness of the data on 
a daily basis. Incomplete and poor-quality 
questionnaires were filled in the next day. The second 
tier was a rejection of the incomplete data for which 
corrections could not be made. 
 
Ethical considerations 
Ethical approval from the Institutional Review Board 
(IRB) of Addis Ababa University – College of Health 
Sciences was obtained. Permission was obtained from 
the registrar office of the hospital after approval by the 
IRB. To ensure the confidentiality of participants’ 
medical records, patient information (such as name and 
telephone number) was not collected. 
 
Methods 
Data were entered into SPSS version 23 for analysis. 
Prevalence was calculated as the percentage of patients 
with ECG-confirmed AF and cardioembolic events 
among the total number of study participants. 
Continuous variables such as age and INR values were 
displayed as medians (interquartile range). Chi-squared 
tests were used to test for the association of 
independent variables with the dependent variables 
(prevalence of AF and embolism). All factors with a p-
value <0.05 in the bivariate analysis were further 




Socio-demographic characteristics and type of valve 
lesions  Of the 833 patient records initially screened for 
the study, a total of 500 (72% female) patients older 
than 13 years of age (median age 29,Interquartile 
Range (IQR) 13.8) fulfilled the inclusion criteria. The 
lack of an electrocardiogram was the primary reason 
for exclusion. Mitral stenosis (MS), defined by mitral 
valve area <2cm2, was the most common valve lesion 
found in 391 (78.2%) of the patients, followed by 
mitral regurgitation (MR) in 348 (69.6%), tricuspid 
regurgitation (TR) in 297 (59.4%) and aortic 
regurgitation (AR) in 240 (48.0%). Close to half 
(49.8%) of these valve lesions were mixed lesions 
(regurgitation and stenosis) of the mitral valve or 
combined aortic and mitral valve lesions. All tricuspid 
lesions were associated with mitral and/or aortic 
lesions. Table 1 shows the socio-demographic 
characteristics of the patients and types of valve 
lesions. 
 
Table 1: Socio-demographic characteristics of the study participants and types  
of valve lesion, 2017 
Variables Number Percent 
Gender 
Female 360 72.0 
Male 140 28.0 
Total 500 100.0 
Age range 
<20 70 14.0 
20-29 199 39.8 
30-39 143 28.6 
40-49 50 10.0 
Above 50 38 7.6 
Total 500 100.0 
Type of valve lesion 
Mitral stenosis 391 78.2 
Mitral regurgitation 348 69.6 
Tricuspid regurgitation 297 59.4 
Aortic regurgitation 240 48.0 
 
Prevalence and determinants of AF: Of the 500 
patients included in the study, 234 (46.8%) had ECG 
evidence of AF. Rates of AF were similar between 
females (47.5%) and males (44.6%), (p=0.6). The 
prevalence of AF was most common in the ≥50 age 
group, and least common in the ≤20 age group 
(p=0.01). Table 2 shows the prevalence of AF across 
different age groups. 
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Nearly a quarter of the study participants were not 
taking benzathine penicillin for secondary prevention 
of RHD. Patients with AF were less likely to take 
prophylaxis than those with no AF (69.7% versus 
83.5%). Other prescribed drugs used were furesmide 
(77.5%), spironolactone (63.4%), digoxin (42.3%), 
warfarin (35.6%), atenolol (36%), metoprolol (12.4%) 
and aspirin (5.4%). Aspirin was prescribed for those 
patients who could not afford INR monitoring with 
warfarin treatment. The presence or absence of non-
valvular risk factors for AF – such as hypertension, 
smoking, diabetes and dyslipidemia – was not recorded 
as primary diagnoses of these patients, but we found 
the number of cases with these risk factors was only 9 
(1.8%) from indirect observation of recorded BP values 
and prescribed medication for these risk factors. 
 
On bivariate analysis using a chi-square test, AF was 
found more in those with TR than without TR (54.4% 
versus 35.8%; p<0.01); more in those with MS than 
with no MS (51.9% versus 28.4%; p <0.01); more in 
those with MR than in those with no MR (49.9% 
versus 39.9%; p=0.31); and where the left atrial size 
was greater than 40mm (p<0.01). AF was found more 
in those with heart failure of at least functional class II 
than in those with no heart failure (47.4% versus 
43.5%; p=0.06). 
 
On multivariable analysis, age ≥50 years (p=0.01), left 
atrial size greater than 45mm (p=0.01), the presence of 
MS (p < 0.01) and the presence of TR (p=0.01) were 
found to be predictors of AF. Table 2 shows the 
association of different variables with the prevalence of 
AF. 
 
Table 2: Multivariable analysis of prevalence of atrial fibrillation with different covariates, 2017 
Variables     Atrial fibrillation Multivariable analysis 







<20 43 (61.4) 27 (38.6) 1.0 
20-29 127 (63.8) 72 (36.2) 0.803 (0.406,1.590) 
30-39 62 (43.4 ) 81 (56.6) 2.093 (1.014-4.316) 
40-49 21 (42.0) 29 (58.0) 1.395 (0.575,3.385) 
Above 50 13 (34.2) 25 (65.8) 3.985 (1.332,11.390) 
 
Mitral stenosis 
Absent 78 (71.6) 31 (28.4) 1.0 
Present 188 (48.1) 203 (51.9) 4.664 (1.996,10.900) 
Mitral regurgitation Absent 92 (60.1) 61 (39.9) 1.0 
Present 174 (50.1) 173 (49.9) 1.592 (0.967,2.620) 
Tricuspid regurgitation Absent 131 (64.2) 73 (35.8) 1.0 
Present 135 (45.6) 161 (54.4) 1.913 (1.213,3.017) 
Left atrial size 
(minor dimensions) 
<40 51 (86.4) 8 (13.6) 1.0 
40-45 70 (83.3) 14 (16.7) 0.843 (0.299,2.372) 
45-50 57 (57.0) 43 (43.0) 3.559 (1.361,9.327) 
>50 88 (34.2) 169 (65.8) 8.064 (3.317,19.603) 
 
Anticoagulation and prevalence of cardioembolic 
events:  Among 234 patients with AF, 178 (76.1%) 
were taking warfarin as an anticoagulant and 10.5% of 
those with no AF were also taking warfarin for a 
presumed cardioembolic event. At least one INR 
determination in the past six months was found for 
82% of those on warfarin. Half of the patients on 
warfarin had average INR values between 2.0 and 4.0, 
and a substantial proportion of patients on warfarin 74 
(40%) had a sub-therapeutic INR (INR values below 2) 
with a median INR of 2.2 and IQR of 1.29; the 
remaining 9.7% had values above 4. 
 
Out of the 500 patients, 67 (9.2%) had presumed 
cardioembolic events. Patients with AF were twice as 
likely to have these events than those with no AF 
(12.4% versus 6.4%; p<0.01). Of the 67 patients with 
cardioembolic events, 41 (61%) had INR values less 
than 2.0. The presence of MS, the absence of MR, left 
atrial size greater than 40mm and INR values less than 
2.0 were found to be predictors of a cardioembolic 
event on bivariate analysis using a chi-square test. 
However, on multivariable analysis, only the presence 
of AF (p=0.02) and an INR value less than 2.0 (p<0.01) 
were related to the occurrence of an acute vascular 
event. Table 3 depicts the relationship between 
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Table 3: Multivariable analysis of cardioembolic event with other covariates, 2017 
Variables Cardioembolic event Multivariable analysis  





Absent 106 (97.2) 3 (2.8) 1.0 
Present 330 (84.4) 61 (15.6) 2.224 (0.473,10.635) 
Mitral regurgitation 
Absent 126 (82.4) 27 (17.6) 0.575 (0.299,0.891) 
Present 310 (89.3) 37 (10.7) 1.0 
Mitral valve area  
>2cmsq 141 (94.0) 9 (6.0) 1.0 
1.5-2.cm2 40 (85.1) 7 (14.9) 0.675 (0.240,1.903) 
1-1.49cm2 109 (90.1) 12 (9.9) 0.893 (0.337,2.391) 
<1cm2 146 (80.2) 36 (19.8) 0.575 (0.266,1.245) 
Left atrial size 
(minor dimensions) 
<40mm 56 (94.9) 3 (5.1) 1.0 
40-45mm 79 (94.0) 5 (6.0) 0.550 (0.105,2.876) 
45-50mm 83 (83.0) 17 (17.0) 0.789 (0.176,3.538) 
>50mm 218 (84.8) 39 (15.2) 0.588 (0.137,2.529) 
Atrial fibrillation 
Absent 245 (92.1) 21 (7.9) 1.0 
Present 191 (81.6) 43 (18.4) 2.624 (1.172,5.877) 
INR values  
INR<2.0 51 (85.6) 9 (14.4) 23.286 (8.289,65.423) 
INR>2.0 85 (94.1) 5 (5.9) 1.0 
 
Discussion 
Our study shows that RHD patients have a high 
prevalence of AF (46.8%), a high prevalence of 
cardioembolic event (9.2%) and a high proportion 
(40%) of sub-therapeutic anticoagulation levels (INR 
values less than 2). The prevalence of AF in our study 
is close to the prevalence of 50% reported in another 
prospective study by Shimada (19), but much higher 
than the 21.8% reported in the REMEDY study (20). 
This could be related to the higher proportion of MS in 
our study (78%) compared to the REMEDY study 
(45%). Approximately 40% of patients initially 
screened for the study had no ECG examination, which 
may underestimate the true prevalence of AF in our 
study. 
 
Age was one of the significant predictors of AF in our 
study, with a marked increase at age ≥50 years. Other 
predictors included the type of valve lesion and left 
atrial size. The highest prevalence was found in those 
patients wth TR. The high prevalence of AF in patients 
with TR may be explained by the fact that such patients 
have a larger right atrial size and elevated right atrial 
pressure, both of which can increase the risk of 
developing AF (21,22). Left atrial size was another 
independent predictor of AF, as shown in several other 
studies. The mean left atrial size in our study was 
significantly larger in patients with AF than patients 
without AF (p= 0.001). Several studies have also 
shown a strong correlation between left atrial size and 
new-onset AF (23,24). 
 
The prevalence of cardioembolic events in our study 
was higher (9.2% versus 5.2%) than that reported in the 
REMEDY study (18). The prevalence of cardioembolic 
events was lower in those with MR than those with no 
MR. This has been shown in transesophageal 
echocardiographic studies, where the presence of 
significant MR is associated with a lower incidence of 
spontaneous echo contrast in the left atrium and thus 
with a lower risk of thrombi and embolization 
compared to rheumatic MS (25,26). In our study, the 
use of oral anticoagulant was slightly better than that of 
the REMEDY study (76.1% versus 69.5%), and of the 
global use of oral anticoagulant (OAC) for non-
valvular AF study (76.1% versus 58%) (20,27) 
However, as in the REMEDY study, a significant 
proportion of patients (40%) on warfarin had a sub-
therapeutic level (INR values less than 2). Lack of 
proper titration of warfarin dose to recommended 
therapeutic INR range and inter-individual variability 
of anticoagulant effects of warfarin could be possible 
explanations for the sub-therapeutic INR values (28). 
The presence of AF and a sub-therapeutic INR level 
were significantly associated with the presumed 
cardioembolic event. 
 
Limitations of the study:  Our study is a retrospective 
review of medical records and may not show the true 
prevalence of AF. A lack of proper documentation for 
other risk factors, such as hypertension, diabetes and 
dyslipidemia, might underestimate the contribution of 
these risk factors to AF. Finally, all patients were from 
a major referral center of the country, which would 
likely attract more severe cases. 
 
Conclusions and recommendations: 
Our study shows a high prevalence of AF and 
cardioembolic events in patients with RHD. Nearly 
half of the patients on oral anticoagulants had 
suboptimal anticoagulation. ECG evaluation of RHD 
patients for detection of AF, and maintenance of 
optimal anticoagulation status for high-risk patients 
with AF, are recommended. 
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